GUTS on Nasdaq

Fractyl (United States)

We are a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (“T2D”).4 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

2010Founded1

Compare with Profusa, Inc., Microbot Medical Inc. or PAVmed Inc., or pick any stock.

  • TickerGUTS on Nasdaq1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersLexington1
  • Websitewww.fractyl.com
  • Incorporated inDE3
  • Business address3 Van De Graaff Drive, Suite 200, Burlington, Ma 018033
  • Filer category, Emerging growth company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (“T2D”). Our Revita ® and Rejuva ® candidates are designed to target root causes of metabolic diseases, allowing us to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-100.0%Revenue growth, 20255
-1490.3%Return on equity5
-$90.9MFree cash flow5

Financial statements

Revenue65$0 in 2025
0$50.0K$100.0K$150.0K2023: $120.0K$120.0K20232024: $93.0K$93.0K2024−22%2025: $0$02025
Gross profit65$43.0K in 2024+0% since 2023
0$20.0K$40.0K$60.0K2023: $43.0K$43.0K20232024: $43.0K$43.0K2024+0%
Operating income65-$96.8M in 2025+90% since 2023
-$100.0M-$75.0M-$50.0M-$25.0M02023: -$50.8M-$50.8M20232024: -$93.5M-$93.5M2024+84%2025: -$96.8M-$96.8M2025+4%
Net income65-$141.0M in 2025+83% since 2023
-$150.0M-$100.0M-$50.0M02023: -$77.1M-$77.1M20232024: -$68.7M-$68.7M2024−11%2025: -$141.0M-$141.0M2025+105%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Revenue$0$93.0K
Cost of goods sold$0$50.0K
Gross Profit$43.0K
Research and development$74.5M$70.5M
Selling, general and administrative$22.3M$23.1M
Total operating expenses$96.8M$93.6M
Loss from operations-$96.8M-$93.5M
Interest income, net$1.5M$4.1M
Change in fair value of notes payable-$4.7M$2.8M
Change in fair value of warrant liabilities-$40.9M$17.9M
Other expense, net-$53.0K-$47.0K
Total other income (expense), net-$44.1M$24.8M
Net loss and comprehensive loss-$141.0M-$68.7M
Accretion of dividends on convertible preferred stock-$1.7M
Net loss attributable to common stockholders-$141.0M-$70.4M
Net loss per share attributable to common stockholders, basic-$1.86-$1.62
Net loss per share attributable to common stockholders, diluted-$1.86-$1.62
Weighted-average number of common shares outstanding, basic75.8M shares43.5M shares
Weighted-average number of common shares outstanding, diluted75.8M shares43.5M shares

Compare Fractyl (United States) with another company

Leadership

Who has led Fractyl (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Harith Rajagopalan2024–now

President

  1. Jay David Caplan2024–now

Chief financial officer

  1. Lisa Davidson2024–2025
  2. Weber Lara Smith2026–now
201520202025
Board members and other officers (12)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerJUAN CARLOS LOPEZ-TALAVERA named Jan 25, 202224
  • DirectorAJAY ROYAN named Jan 25, 202224
  • DirectorBRIAN DOVEY named Jan 25, 202224
  • DirectorWILLIAM BRADLEY named Jan 25, 202224

Former names

  • Fractyl Laboratories Inc.Mar 21, 2013 to Mar 19, 20203

Timeline

  1. Feb 1, 2024New chief executive Harith Rajagopalan becomes CEO9
  2. 2010Founded Founded1

Filings

216 filings to the SEC since October 2021: 3 annual reports, 8 quarterly reports, 44 major events, 90 insider forms, 18 large holders, 1 private raises, 52 other. The latest 20:

  1. Oct 13, 2026SCHEDULE 13G EDGAR
  2. Oct 1, 20268-K EDGAR
  3. Sep 24, 20268-K EDGAR
  4. Sep 16, 20264 EDGAR
  5. Sep 11, 20268-K EDGAR
  6. Aug 24, 2026DEF 14A EDGAR
  7. Aug 14, 2026PRE 14A EDGAR
  8. Aug 10, 202610-Q EDGAR
  9. Aug 10, 20268-K EDGAR
  10. Jul 15, 20268-K EDGAR
  11. Jun 15, 20264 EDGAR
  12. Jun 11, 20268-K EDGAR
  13. Jun 11, 20264 EDGAR
  14. Jun 11, 20264 EDGAR
  15. Jun 11, 20264 EDGAR
  16. Jun 11, 20264 EDGAR
  17. Jun 11, 20264 EDGAR
  18. Jun 11, 20264 EDGAR
  19. Jun 11, 20264 EDGAR
  20. Jun 11, 20264 EDGAR

The 216 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

23 open-market trades by officers, directors and large owners since October 2021: 16 buys and 7 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 14, 2026BRADLEY WILLIAMDirectorBuy64,516$0.62$40.0KForm 4
Jun 12, 2026Royan AjayDirectorBuy23,000$0.85$19.6KForm 4
Jun 10, 2026BRADLEY WILLIAMDirectorBuy68,493$0.73$50.0KForm 4
Jun 10, 2026Sheffield IanDirectorBuy35,000$0.73$25.6KForm 4
Jun 10, 2026Rajagopalan HarithChief Executive OfficerBuy25,000$0.73$18.2KForm 4
Jun 8, 2026Smith Weber LaraChief Financial OfficerBuy20,000$0.69$13.8KForm 4
Dec 4, 2025Rajagopalan HarithChief Executive OfficerBuy10,416$1.92$20.0KForm 4
Mar 14, 2025Royan AjayDirectorBuy17,901$1.28$22.9KForm 4
Mar 14, 2025Barnes Kelly AnnDirectorBuy31,000$1.30$40.3KForm 4
Mar 13, 2025SCHULMAN AMY WDirectorBuy8,550$1.17$10.0KForm 4
Mar 13, 2025BRADLEY WILLIAMDirectorBuy16,129$1.26$20.3KForm 4
Mar 13, 2025Conaway SamuelDirectorBuy8,550$1.17$10.0KForm 4
Jan 31, 2025Rajagopalan HarithChief Executive OfficerSale90,972$1.82$165.6KForm 4
Jan 31, 2025Caplan Jay DavidPresident, Chief Product Off.Sale22,346$1.81$40.4KForm 4
Jan 30, 2025Rajagopalan HarithChief Executive OfficerSale20,948$1.95$40.8KForm 4
Jan 30, 2025Caplan Jay DavidPresident, Chief Product Off.Sale21,472$1.95$41.9KForm 4
Nov 11, 2024Rajagopalan HarithChief Executive OfficerSale96,517$2.47$238.4KForm 4
Nov 11, 2024Caplan Jay DavidPresident, Chief Product Off.Sale64,197$2.47$158.6KForm 4
Sep 12, 2024Caplan Jay DavidPresident, Chief Product Off.Sale65,000$2.90$188.5KForm 4
Feb 6, 2024Royan AjayDirectorBuy333,333$15.00$5.0MForm 4

All 23 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jan 11, 2022Raised $20.1 million in a private offering of debt Form D: 4 investors so far Form D

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36